|
| 37438903 | Research of Active Compounds from and Potential Targets against Non-Hodgkin's Lymphoma Based on Network Pharmacology. | | 2024 |
| 36859267 | Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial. | | 2023 |
| 32554706 | mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. | Science Translational Medicine | 2020 |
| 31942075 | B cells and tertiary lymphoid structures promote immunotherapy response. | Nature | 2020 |
| 33046869 | Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. | Nat Med | 2020 |
| 31112940 | Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation. | Acta Haematol | 2019 |
| 31734631 | Genome-Wide Profiling of Acquired Uniparental Disomy Reveals Prognostic Factors in Head and Neck Squamous Cell Carcinoma. | Neoplasia | 2019 |
| 30518672 | Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast Cancer. | Mol Cancer Ther | 2019 |
| 29725014 | Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. | Nat Commun | 2018 |
| 29959144 | Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells. | Clin Cancer Res | 2018 |
| 29622464 | A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. | Cancer Cell | 2018 |
| 28196595 | Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. | Cancer Cell | 2017 |
| 28659338 | High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. | Haematologica | 2017 |
| 28559461 | The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. | Clin Cancer Res | 2017 |
| 27524414 | Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression. | Oncogene | 2017 |
| 26606000 | Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis. | Hepatology | 2016 |
| 27172895 | High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. | Clin Cancer Res | 2016 |
| 26865225 | Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. | Oncogene | 2016 |
| 27160903 | Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. | Cell Rep | 2016 |
| 26061751 | Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. | N Engl J Med | 2015 |
| 25629879 | Corrigendum: A pan-cancer proteomic perspective on The Cancer Genome Atlas. | Nat Commun | 2015 |
| 25724525 | A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. | Clin Cancer Res | 2015 |
| 25380958 | Development of a robust classifier for quality control of reverse-phase protein arrays. | Bioinformatics | 2015 |
| 26080861 | Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. | Nat Commun | 2015 |
| 24871328 | A pan-cancer proteomic perspective on The Cancer Genome Atlas. | Nat Commun | 2014 |
| 25501559 | Spatial normalization of reverse phase protein array data. | PLoS One | 2014 |
| 25374453 | A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data. | Cancer Inform | 2014 |
| 25490449 | Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. | Cancer Cell | 2014 |
| 24583795 | Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. | Clin Cancer Res | 2014 |
| 24979294 | Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. | Oncotarget | 2014 |
| 24752867 | Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. | Cancer | 2014 |
| 25117710 | Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. | Cancer Cell | 2014 |
| 23472141 | Identification and characterization of microRNAs controlled by the osteoblast-specific transcription factor Osterix. | PLoS One | 2013 |
| 24037243 | TCPA: a resource for cancer functional proteomics data. | Nat Methods | 2013 |
| 24055055 | Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. | Cell Rep | 2013 |
| 22223528 | Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. | Clin Cancer Res | 2012 |
| 22479189 | LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. | PLoS Genet | 2012 |
| 22961666 | Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. | Cancer Discov | 2012 |
| 22826565 | Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. | Blood | 2012 |
| 23006314 | An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. | Proteome Sci | 2012 |
| 21906370 | Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. | Clin Proteomics | 2011 |
| 21691416 | A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. | Clin Proteomics | 2010 |
| 21082038 | Blasted cell line names. | Cancer Inform | 2010 |
| 20124458 | Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. | Mol Cancer Ther | 2010 |
| 20363357 | Molecular signatures and biological pathway profiles of human corneal epithelial progenitor cells. | International Journal of Biochemistry and Cell Biology | 2010 |
| 19477432 | Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. | Cancer Cell | 2009 |
| 19440550 | Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. | PLoS One | 2009 |
| 19176552 | Serial dilution curve: a new method for analysis of reverse phase protein array data. | Bioinformatics | 2009 |
| 19435916 | Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. | Cancer Res | 2009 |
| 17213798 | Gene expression profiling in embryonic mouse lenses. | Molecular Vision | 2006 |